本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 重庆西山科技股份有限公司（以下简称"公司"）第四届监事会第七次会议于 2025 年 8 月 29 日 14:00 以现场结合通讯会议方式在公司会议室召开。应出席会 议监事 3 名，实际出席会议监事 3 名，会议由监事会主席常婧召集和主持。会议 通知于 2025 年 8 月 19 日通过书面方式和电话等方式发出。 本次会议的召开符合《中华人民共和国公司法》（以下简称"《公司法》"） 和《重庆西山科技股份有限公司公司章程》（以下简称"《公司章程》"）的有关 规定。 证券代码：688576 证券简称：西山科技 公告编号：2025-034 二、监事会会议审议情况 重庆西山科技股份有限公司 第四届监事会第七次会议决议公告 庆西山科技股份有限公司 2025 年半年度报告》及《重庆西山科技股份有限公司 2025 年半年度报告摘要》。 （二）审议通过《关于公司<2025 年半年度募集资金存放与实际使用情况的 专项报告>的议案》 公司基于 2025 年上半年募集资金存放 ...

Group 1 - On August 27, a block trade of 800,000 shares of Aotwei was executed, with a transaction amount of 31.68 million yuan, accounting for 7.41% of the total transaction volume for the day [1] - The transaction price was 39.6 yuan, which represents a discount of 1.02% compared to the market closing price of 40.01 yuan [1]

Company Overview - Xishan Technology's closing price on August 14 was 70.46 yuan, down 4.03%, with a rolling PE ratio of 38.05 times and a total market capitalization of 3.206 billion yuan [1] - The company operates in the surgical medical device sector, focusing on the research, manufacturing, sales, and service of surgical power devices, endoscopic systems, and energy surgical equipment [1] Financial Performance - For the first quarter of 2025, Xishan Technology reported revenue of 65.8771 million yuan, a year-on-year decrease of 11.20%, and a net profit of 11.4768 million yuan, down 55.66% year-on-year, with a gross margin of 67.64% [1] Industry Comparison - The average PE ratio for the medical device industry is 55.76 times, with a median of 39.14 times, placing Xishan Technology at the 75th position in the industry ranking [1] - The company’s static PE ratio is 32.49 times, and its price-to-book ratio is 1.85 times [2]

证券日报网讯西山科技8月14日在互动平台回答投资者提问时表示，截至2025年8月8日，公司股东人数 为5309户。 ...

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Xishan Technology in the medical device industry, noting its current stock price and market capitalization [1][2] - As of August 12, Xishan Technology's stock closed at 74.63 yuan, with a PE ratio of 40.30, marking a new low in 209 days, and a total market value of 3.396 billion yuan [1] - The average PE ratio for the medical device industry is 57.51, with a median of 41.25, positioning Xishan Technology at the 75th rank within the industry [1][2] Group 2 - Xishan Technology's main business involves the research, manufacturing, sales, and service of surgical medical devices, including surgical power tools, endoscopic systems, and energy surgical equipment [1] - The latest financial results for Q1 2025 show that the company achieved a revenue of 65.8771 million yuan, a year-on-year decrease of 11.20%, and a net profit of 11.4768 million yuan, down 55.66% year-on-year, with a gross margin of 67.64% [1]

Company Overview - Xishan Technology's closing price on August 8 was 72.56 yuan, up 1.94%, with a rolling PE ratio of 39.18, marking a new low in 207 days, and a total market capitalization of 3.301 billion yuan [1] - The company operates in the surgical medical device sector, focusing on the research, manufacturing, sales, and service of surgical instruments, including surgical power devices, endoscopic systems, and energy surgical equipment [1] Financial Performance - For the first quarter of 2025, Xishan Technology reported revenue of 65.8771 million yuan, a year-on-year decrease of 11.20%, and a net profit of 11.4768 million yuan, down 55.66% year-on-year, with a gross profit margin of 67.64% [1] Industry Comparison - The average PE ratio for the medical device industry is 55.70, with a median of 39.08, placing Xishan Technology at the 77th position in the industry ranking [1] - The company’s static PE ratio is 33.46, and its price-to-book ratio is 1.91 [2]

Core Insights - The report highlights that the total salary of A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 company secretaries earned over 1 million yuan, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary of company secretaries in the medical consumables sector is 817,000 yuan [2] - Salary distribution among company secretaries is as follows: below 500,000 yuan (30%), 500,000-1,000,000 yuan (41%), 1,000,000-2,000,000 yuan (27%), and above 2,000,000 yuan (2%) [2] - The top three highest-paid company secretaries are: Gong Xingliang from Nanwei Medical (2.2161 million yuan), Zhu Yu from Microelectrophysiology (1.6764 million yuan), and Lin Qing from Weigao Orthopedics (1.6142 million yuan) [2] Age and Education Distribution - The age distribution of company secretaries shows that those aged 40-50 constitute 45%, while those over 50 account for 14%, and those aged 30-40 make up 36% [1] - The educational background of company secretaries is as follows: 7% have an associate degree, 45% hold a bachelor's degree, 43% possess a master's degree, and 5% have a doctoral degree [1] Salary Changes - Among company secretaries with over two years of tenure, the largest salary decrease was observed for Bai Xue from Xishan Technology, with a year-on-year decline of 54.09% [2] - The highest salary increase was recorded for Chen Bin from Weili Medical, with a year-on-year increase of 191.72% [2]

Group 1 - The core viewpoint of the news is that Xishan Technology's stock performance and financial metrics indicate a challenging position within the medical device industry, with a notably low PE ratio compared to industry averages [1][2] - As of August 5, Xishan Technology's closing price was 72.11 yuan, with a rolling PE ratio of 38.94, marking a 204-day low and a total market capitalization of 3.281 billion yuan [1] - The average PE ratio for the medical device industry is 54.24, with a median of 37.92, placing Xishan Technology at the 78th position in the industry ranking [1][2] Group 2 - The latest quarterly report for Q1 2025 shows Xishan Technology achieved revenue of 65.8771 million yuan, a year-on-year decrease of 11.20%, and a net profit of 11.4768 million yuan, down 55.66% [1] - The company's gross profit margin stands at 67.64%, indicating a relatively high profitability despite the decline in revenue and net profit [1] - Xishan Technology specializes in the research, manufacturing, sales, and service of surgical medical devices, with key products including surgical power tools, endoscopic systems, and energy surgical equipment [1]

Core Viewpoint - The recent personnel changes at Xishan Technology reflect the company's ongoing transformation and the challenges it faces in maintaining growth amid declining profits and market pressures [1][4][12]. Group 1: Personnel Changes - The Vice President Bian Benben has submitted his resignation to focus on his role as the National Sales Director, effective July 28, 2025 [3][4]. - Bian, who joined the company in 2006, saw his annual salary drop from 1.08 million yuan in 2023 to 634,100 yuan in 2024, indicating significant performance pressures [3][4]. Group 2: Financial Performance - Xishan Technology's net profit fell by 15.92% in 2024, with a staggering 55.66% decline in the first quarter of 2025 [4][12]. - The company's stock price has plummeted nearly 70% from its peak of 135.8 yuan per share in June 2023 to 69.70 yuan as of July 29, 2024, despite a 14% increase in 2025 [5][12]. Group 3: Shareholder Actions - To restore market confidence, the controlling shareholder, Xishan Investment, plans to buy back shares worth between 5 million and 10 million yuan within six months [5][6]. - Xishan Investment and its concerted parties hold a total of 23.75 million shares, representing 52.20% of the company [6][7]. Group 4: Strategic Shifts - Xishan Technology is transitioning from traditional surgical power devices to becoming a comprehensive provider of minimally invasive surgical tools, with a focus on breaking foreign monopolies [9][11]. - The company is expanding into the endoscope market, moving from rigid to flexible endoscopes, which could open new growth avenues as domestic production rates increase [10][11]. Group 5: Future Outlook - The personnel changes and strategic shifts signify a critical phase for Xishan Technology, as it seeks to regain control and drive innovation in the face of declining traditional revenue streams [12].

Group 1 - The company announced the resignation of Vice General Manager Bian Benben due to personal reasons, effective from July 28, 2025, while he will continue to serve as the National Sales Director [1][2] - Bian Benben's resignation will not affect the company's normal operations and management, as stated in accordance with relevant laws and regulations [2] - Bian Benben holds 22,000 shares in the company through a holding platform and will comply with relevant regulations regarding shareholding and commitments made during the initial public offering [2]